GeNeuro Announces the Approval of all Resolutions proposed at the AGM
Geneva, Switzerland, May 28, 2020 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis, today announced the approval by shareholders of all resolutions proposed at its Annual General Meeting (AGM) of May 27, 2020. https://geneuro.ch/data/news/2020.05.28-GeNeuro-AGM-28052020-ENG.pdf